Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.34 |
| ▸ | USP2 | O75604 | 3/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | KRAS | P01116 | 1/20 | 0.32 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | ADAM10 | O14672 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL1623567 | 0.90 | CHEK2 (0.39) | CYP1A2CYP3A4CYP2D6USP2CLK4 | |
| SCHEMBL1623699 | 0.88 | CHEK2 (0.41) | CYP1A2CYP3A4CYP2D6USP2CLK4 | |
| SCHEMBL1623697 | 0.88 | CHEK2 (0.41) | CYP1A2CYP3A4CYP2D6USP2CLK4 | |
| SCHEMBL1623696 | 0.88 | CHEK2 (0.41) | CYP1A2CYP3A4CYP2D6USP2CLK4 | |
| SCHEMBL5502660 | 0.80 | KMT2A (0.41) | CYP1A2CYP3A4CYP2D6MAPK1TSHR | |
| SCHEMBL1623961 | 0.79 | CHEK2 (0.39) | CYP1A2CYP3A4CYP2D6USP2CLK4 | |
| SCHEMBL1623964 | 0.79 | CHEK2 (0.39) | CYP1A2CYP3A4CYP2D6USP2CLK4 | |
| SCHEMBL1623960 | 0.79 | CHEK2 (0.39) | CYP1A2CYP3A4CYP2D6USP2CLK4 | |
| SCHEMBL12759621 | 0.79 | CHEK2 (0.38) | CYP1A2CYP3A4CYP2D6USP2CLK4 | |
| SCHEMBL12721181 | 0.75 | MEN1 (0.46) | CYP1A2CYP3A4CYP2D6USP2CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283354-B2 | Voltage gated sodium and calcium channel inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-09 | — | — | US | disclosed |
| US-7928107-B2 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-19 | — | — | US | disclosed |
| US-20090312342-A1 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2009-12-17 | — | — | US | disclosed |
| EP-1784393-B1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20060173018-A1 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312342-A1 | Quinazolines useful as modulators of ion channels | KCNQ1, KCNQ2, KCNN3 | CYP1A2 2466/4885CYP3A4 2278/4885CYP2D6 2211/4885 |
| US-20060173018-A1 | Quinazolines useful as modulators of ion channels | KCNQ1, KCNQ2, KCNN3 | CYP1A2 2466/4885CYP3A4 2278/4885CYP2D6 2211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.